• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

镰刀菌病的新治疗选择:专利综述(2008 - 2023年)

New Therapeutic Options for Fusariosis: A Patent Review (2008-2023).

作者信息

Faccin Izadora Dillis, Salomé Túlio Máximo, de Almeida de Souza Gleyce Hellen, da Costa Xavier Leonardo, Alves Izabel Almeida, Lima Vanessa Castro Felix, Lucini Fabíola, Simionatto Simone, Rossato Luana

机构信息

Health Sciences Research Laboratory, Universidade Federal of Grande Dourados, 79804-970 Dourados, Brazil.

Pharmacokinetics and Pharmacometrics Laboratory, Universidade Federal da Bahia, 40110-909 Salvador, Brazil.

出版信息

J Fungi (Basel). 2025 Jun 18;11(6):463. doi: 10.3390/jof11060463.

DOI:10.3390/jof11060463
PMID:40558974
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12194352/
Abstract

Fusariosis is an infection caused by the fungus spp., which is pathogenic to both plants and humans. The disease presents several clinical manifestations and epidemiological patterns. Current treatment relies on azoles and polyenes, but increasing antifungal resistance requires the exploration of new therapeutic options. This study reviewed patents related to the treatment of Fusariosis from the last 15 years (up to June 2023). The search identified 318 patents, categorized by identification code, publication date, type of application and mechanism of action, using the International Patent Classification and Cooperative Patent Classification systems. In addition, we conducted a bibliographic search in the PubMed database using the same criteria to identify the number of scientific articles. Of the 318 patents, 21 targeted Fusarium infections in humans. The years 2014 and 2018 stood out with three patents each, while the same period recorded an average of 58 published articles. The patents addressed mechanisms such as drug delivery, gene expression, immunotherapy, engineered drugs, and novel compounds. This research highlights the urgent need for continued innovation in therapeutic technologies to effectively treat wilt.

摘要

镰刀菌病是一种由镰刀菌属真菌引起的感染,这种真菌对植物和人类均具有致病性。该疾病呈现出多种临床表现和流行病学模式。目前的治疗依赖于唑类和多烯类药物,但不断增加的抗真菌耐药性促使人们探索新的治疗选择。本研究回顾了过去15年(截至2023年6月)与镰刀菌病治疗相关的专利。通过使用国际专利分类和合作专利分类系统,检索确定了318项专利,并按识别代码、公布日期、申请类型和作用机制进行了分类。此外,我们使用相同标准在PubMed数据库中进行了文献检索,以确定科学文章的数量。在这318项专利中,有21项针对人类镰刀菌感染。2014年和2018年各有三项专利脱颖而出,而同一时期平均有58篇发表文章。这些专利涉及药物递送、基因表达、免疫疗法、工程药物和新型化合物等机制。这项研究凸显了治疗技术持续创新以有效治疗镰刀菌病的迫切需求。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d062/12194352/265c454c6e6f/jof-11-00463-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d062/12194352/65b3b32826c4/jof-11-00463-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d062/12194352/265c454c6e6f/jof-11-00463-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d062/12194352/65b3b32826c4/jof-11-00463-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d062/12194352/265c454c6e6f/jof-11-00463-g002.jpg

相似文献

1
New Therapeutic Options for Fusariosis: A Patent Review (2008-2023).镰刀菌病的新治疗选择:专利综述(2008 - 2023年)
J Fungi (Basel). 2025 Jun 18;11(6):463. doi: 10.3390/jof11060463.
2
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
3
Host-specific adaptation in correlates with distinct accessory chromosome content in human and plant pathogenic strains.宿主特异性适应与人类和植物致病菌株中不同的附加染色体含量相关。
mBio. 2025 Jun 26:e0095125. doi: 10.1128/mbio.00951-25.
4
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
5
Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients.用于预防非中性粒细胞减少的重症患者真菌感染的抗真菌药物。
Cochrane Database Syst Rev. 2016 Jan 16;2016(1):CD004920. doi: 10.1002/14651858.CD004920.pub3.
6
Antibiotics for exacerbations of asthma.用于哮喘加重期的抗生素
Cochrane Database Syst Rev. 2018 Jun 25;6(6):CD002741. doi: 10.1002/14651858.CD002741.pub2.
7
Aerobic exercise interventions for adults living with HIV/AIDS.针对感染艾滋病毒/艾滋病的成年人的有氧运动干预措施。
Cochrane Database Syst Rev. 2005 Apr 18(2):CD001796. doi: 10.1002/14651858.CD001796.pub2.
8
Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation.首次就诊时磁共振灌注成像用于鉴别低级别与高级别胶质瘤
Cochrane Database Syst Rev. 2018 Jan 22;1(1):CD011551. doi: 10.1002/14651858.CD011551.pub2.
9
Dressings and topical agents for treating pressure ulcers.用于治疗压疮的敷料和外用剂。
Cochrane Database Syst Rev. 2017 Jun 22;6(6):CD011947. doi: 10.1002/14651858.CD011947.pub2.
10
Eliciting adverse effects data from participants in clinical trials.从临床试验参与者中获取不良反应数据。
Cochrane Database Syst Rev. 2018 Jan 16;1(1):MR000039. doi: 10.1002/14651858.MR000039.pub2.

本文引用的文献

1
Antimicrobial peptides against polymyxin-resistant Klebsiella pneumoniae: a patent review.抗多黏菌素耐药肺炎克雷伯菌的抗菌肽:专利述评。
World J Microbiol Biotechnol. 2023 Feb 1;39(3):86. doi: 10.1007/s11274-023-03530-6.
2
Identification of novel inhibitors of high affinity iron permease (FTR1) through implementing pharmacokinetics index to fight against black fungus: An in silico approach.通过应用药代动力学指标对抗黑真菌来鉴定新型高亲和力铁通透酶(FTR1)抑制剂:一种计算机模拟方法。
Infect Genet Evol. 2022 Dec;106:105385. doi: 10.1016/j.meegid.2022.105385. Epub 2022 Nov 8.
3
Tafenoquine exhibits broad spectrum antifungal activity at clinically relevant concentrations and decreases lung fungal burden in an invasive pulmonary model of .
tafenoquine在临床相关浓度下表现出广谱抗真菌活性,并在侵袭性肺部模型中降低肺部真菌负荷。
New Microbes New Infect. 2022 Feb 4;45:100964. doi: 10.1016/j.nmni.2022.100964. eCollection 2022 Jan.
4
Viral vector-based gene therapies in the clinic.临床中基于病毒载体的基因疗法。
Bioeng Transl Med. 2021 Oct 20;7(1):e10258. doi: 10.1002/btm2.10258. eCollection 2022 Jan.
5
Preparation of Topical Itraconazole with Enhanced Skin/Nail Permeability and In Vivo Antifungal Efficacy against Superficial Mycosis.具有增强的皮肤/指甲渗透性及体内抗浅表真菌病抗真菌功效的外用伊曲康唑的制备
Pharmaceutics. 2021 Apr 27;13(5):622. doi: 10.3390/pharmaceutics13050622.
6
Current applications and prospects of nanoparticles for antifungal drug delivery.纳米颗粒用于抗真菌药物递送的当前应用与前景
EXCLI J. 2021 Mar 8;20:562-584. doi: 10.17179/excli2020-3068. eCollection 2021.
7
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.PRISMA 2020 声明:系统评价报告的更新指南。
BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71.
8
Advances in Fusarium drug resistance research.镰刀菌耐药性研究进展。
J Glob Antimicrob Resist. 2021 Mar;24:215-219. doi: 10.1016/j.jgar.2020.12.016. Epub 2021 Jan 15.
9
Sample Preparation of Posaconazole Oral Suspensions for Identification of the Crystal Form of the Active Pharmaceutical Ingredient.泊沙康唑口服混悬剂样品制备用于鉴定活性药物成分的晶体形式。
Molecules. 2020 Dec 19;25(24):6032. doi: 10.3390/molecules25246032.
10
Increased incidence of candidemia in a tertiary care hospital with the COVID-19 pandemic.在 COVID-19 大流行期间,一家三级保健医院的念珠菌血症发病率上升。
Mycoses. 2021 Feb;64(2):152-156. doi: 10.1111/myc.13225. Epub 2020 Dec 10.